Attendees who purchased access to the 2016 Annual Meeting webcast were sent login information on May 11, 2016.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 9 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 8 9 presentations: 1 to 25 of 203
Keynote Talks
Lessons from resistance to targeted agents
Dr. Charles L. Sawyers
Memorial Sloan-Kettering Cancer Center, New York, NY
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 8:05 AM-10:05 AM
Keynote Talks
Identifying tumour-specific targets: The role of clinical translational data
Prof. A. Hilary Calvert
University College London Partners, London, England
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 8:05 AM-10:05 AM
Plenary Session 1: Drug Responses in Genetically-Engineered Mouse Models for Cancer
The Co-clinical trial project
Dr. Pier Paolo Pandolfi
Beth Israel Deaconess Medical Center, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 10:30 AM-12:30 PM
Plenary Session 1: Drug Responses in Genetically-Engineered Mouse Models for Cancer
The use of genetically engineered mouse lung cancer models for testing of novel therapeutics
Dr. Kwok-Kin Wong
Dana-Farber Cancer Institute, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 10:30 AM-12:30 PM
Plenary Session 1: Drug Responses in Genetically-Engineered Mouse Models for Cancer
Targeting PI3Kinases in Cancer: Could Isoform specificity really matter?
Dr. Thomas M. Roberts
Dana-Farber Cancer Institute, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 10:30 AM-12:30 PM
Plenary Session 2: Targeting the PI3K Pathway
Targeting the PI3K pathway in cancer
Dr. William R. Sellers
Novartis Institutes for BioMedical Research, Cambridge, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 2:30 PM-4:30 PM
Plenary Session 2: Targeting the PI3K Pathway
Growth control by the mTOR pathway
Dr. David M. Sabatini
MIT Whitehead Institute for Biomedical Research, Cambridge, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 2:30 PM-4:30 PM
Plenary Session 2: Targeting the PI3K Pathway
Targeting PI3K in Breast Cancer
Dr. Jean J. Zhao
Dana-Farber Cancer Institute, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 2:30 PM-4:30 PM
Plenary Session 2: Targeting the PI3K Pathway
Finding biomarkers of resistance to EGFR targeted therapy in cancer
Dr. René Bernards
The Netherlands Cancer Institute, Amsterdam, The Netherlands
from 2009 Molecular Targets and Cancer Therapeutics conference on November 16, 2009 2:30 PM-4:30 PM
Plenary Session 3: Acquired Drug Resistance
Lessons learned from acquired resistance to kinase inhibitors in chronic myeloid leukemia
Dr. Neil P. Shah
UCSF Comprehensive Cancer Center, San Francisco, CA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 8:00 AM-10:00 AM
Plenary Session 3: Acquired Drug Resistance
Epigenetics of resistance to endocrine therapy
Dr. Myles A. Brown
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 8:00 AM-10:00 AM
Plenary Session 4: Targeting Tumor Cell Metabolism
Validating metabolic targets for cancer therapy
Dr. Craig B. Thompson
University of Pennsylvania, Philadelphia, PA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 10:30 AM-12:30 PM
Plenary Session 4: Targeting Tumor Cell Metabolism
Tumour Cell Survival Under Metabolic Stress
Dr. Tak W. Mak
University of Toronto, Toronto, ON, Canada
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 10:30 AM-12:30 PM
Plenary Session 4: Targeting Tumor Cell Metabolism
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dr. David Schenkein
Agios Pharmaceuticals, Cambridge, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 10:30 AM-12:30 PM
Plenary Session 4: Targeting Tumor Cell Metabolism
Extracellular matrix control of tumor cell metabolism
Dr. Joan S. Brugge
Harvard Medical School, Boston, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 10:30 AM-12:30 PM
Plenary Session 4: Targeting Tumor Cell Metabolism
Tumor cell metabolism in the response to chemotherapy
Dr. Guido Kroemer
Institut Gustave-Roussy, Villejuif, France
from 2009 Molecular Targets and Cancer Therapeutics conference on November 17, 2009 10:30 AM-12:30 PM
Plenary Session 5: The Cancer Genome
Translational pharmacogenomics
Dr. Spyro Mousses
Translational Genomics Research Institute, Scottsdale, AZ
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 8:00 AM-10:00 AM
Plenary Session 5: The Cancer Genome
Challenges of Targeted Therapy: KRAS
Dr. Frank McCormick
UCSF Comprehensive Cancer Center, San Francisco, CA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 8:00 AM-10:00 AM
Plenary Session 6: The Cancer Epigenome
Targeted inhibition of chromatin modifying enzymes as cancer therapeutics: The HDAC inhibitor vorinostat and beyond
Dr. Victoria M. Richon
EpiZyme, Inc., Cambridge, MA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 10:30 AM-12:30 PM
Plenary Session 6: The Cancer Epigenome
Sensitivity and Resistance to DNA Hypomethylators
Dr. Jean-Pierre J. Issa
UT M.D. Anderson Cancer Center, Houston, TX
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 10:30 AM-12:30 PM
Plenary Session 6: The Cancer Epigenome
Cellular Reprogramming: Clues to Establishing, and Targeting, the Cancer Epigenome
Dr. Stephen B. Baylin
Johns Hopkins University School of Medicine, Baltimore, MD
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 10:30 AM-12:30 PM
Plenary Session 6: The Cancer Epigenome
Cracking chromatin open with DNA methylation inhibitors
Dr. Peter A. Jones
USC/Norris Comprehensive Cancer Center, Los Angeles, CA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 18, 2009 10:30 AM-12:30 PM
Plenary Session 7: Targeting the Tumor Microenvironment
Targeting mechanisms of evasive resistance to anti-angiogenic therapies
Dr. Douglas Hanahan
UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 19, 2009 8:00 AM-10:00 AM
Plenary Session 7: Targeting the Tumor Microenvironment
Cancer and inflammation: Common pathways and targets
Dr. Frances R. Balkwill
Barts & The London School of Medicine & Dentistry, London, England
from 2009 Molecular Targets and Cancer Therapeutics conference on November 19, 2009 8:00 AM-10:00 AM
Plenary Session 7: Targeting the Tumor Microenvironment
Targeting the hedgehog pathway in cancer: from bench to clinic
Dr. Frederic J. de Sauvage
Genentech, Inc., South San Francisco, CA
from 2009 Molecular Targets and Cancer Therapeutics conference on November 19, 2009 8:00 AM-10:00 AM
<< first | < prev page: of 9 records per page: next > | last >>
pages: 1 2 3 4 5 6 7 8 9 presentations: 1 to 25 of 203